Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 a year ago.The reported revenue represents a surprise of +3.88% over the Zacks Consensus Estimate of $128.99 million. With the consensus EPS estimate being -$1.16, the EPS surprise was +18.10%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Commercial Revenue- Licensing and royalty revenue: $5 million compared to the $5.51 million average estimate based on nine analysts. The reported number represents a change of -44.4% year over year. Revenue- Research and development revenue under collaborative agreements: $45 million compared to the $49.79 million average estimate based on eight analysts. The reported number represents a change of -25% year over year. Revenue- Commercial Revenue- Spinraza royalties: $57 million versus $61.92 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -14.9% change. Revenue- Commercial Revenue- Tegsedi and Waylivra revenue, net: $9 million compared to the $7.71 million average estimate based on eight analysts. The reported number represents a change of +12.5% year over year. Revenue- Total commercial revenue: $76 million compared to the $79.73 million average estimate based on eight analysts. The reported number represents a change of -9.5% year over year. Revenue- R&D Revenue- Collaborative agreement revenue: $45 million versus $33.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.3% change. Revenue- R&D Revenue- Amortization from upfront payments: $28 million versus $35.30 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +55.6% change. Revenue- R&D Revenue- WAINUA joint development revenue: $13 million versus the two-analyst average estimate of $15.75 million. The reported number represents a year-over-year change of -18.8%. View all Key Company Metrics for Ionis Pharmaceuticals here>>>Shares of Ionis Pharmaceuticals have returned +2.7% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks